高精度持续循环腹腔热灌注化疗联合静脉化疗治疗晚期卵巢癌的安全性和有效性分析

Safety and efficacy analysis of high-precision continuous-circulation intraperitoneal hyperthermic chemotherapy combined with intravenous chemotherapy in the treatment of ovarian cancer

目的探讨高精度持续循环腹腔热灌注化疗联合静脉化疗与常规静脉化疗治疗晚期卵巢癌的疗效及安全性。方法回顾性分析96例临床分期为Ⅲ～Ⅳ期的卵巢癌患者的病历资料,根据化疗方式的不同将患者分为观察组和对照组,每组48例。观察组患者接受高精度持续循环腹腔热灌注化疗联合静脉化疗,对照组患者接受常规静脉化疗。化疗6个周期后,比较两组患者的近期疗效和不良反应发生情况,并对两组患者的远期生存情况进行比较。结果观察组患者的近期疗效优于对照组,疾病控制率高于对照组,差异均有统计学意义(P﹤0.05);两组患者的缓解率比较,差异无统计学意义(P﹥0.05)。观察组患者胃肠道反应、心脏不良反应、周围神经不良反应、肾功能不全、肝功能不全、骨髓抑制的发生率与对照组比较,差异均无统计学意义(P﹥0.05)。观察组患者的3年生存情况优于对照组,差异有统计学意义(P﹤0.05)。结论高精度持续循环腹腔热灌注化疗联合静脉化疗治疗晚期卵巢癌较常规静脉化疗的近期疗效好、3年生存率高,且未增加不良反应的发生风险,是一种安全可靠的治疗方式。

Objective To explore the safety and efficacy of high-precision continuous-circulation intraperitoneal hyperthermic chemotherapy(IPHC)combined with intravenous chemotherapy in the treatment of ovarian cancer.Method The medical records of96patients with stage III-IV ovarian cancer were retrospectively analyzed and the patients were divided into observation group and control group according to different chemotherapy regimens,48cases in each group.Patients in the observation group received high-precision continuous-circulation IPHC combined with intravenous chemotherapy while patients in the control group received conventional intravenous chemotherapy.After6cycles of chemotherapy,the short-term efficacy and adverse reactions of the two groups were compared,and the long-term survival of the two groups was compared.Result The short-term efficacy of the observation group was better than that of the control group,and the disease control rate was higher than that of the control group,the differences were statistically significant(P<0.05).There was no significant difference in the remission rate of patients between the two groups(P>0.05).There was no significant difference in incidences of gastrointestinal reactions,adverse cardiac reactions,peripheral neuropathy,renal insufficiency,hepatic insufficiency,and myelosuppression between the two group(P>0.05).The3-year survival of patients in the observation group was significantly better than that of the control group(P<0.05).Conclusion Compared with conventional intravenous chemotherapy,high-precision continuous-circulation IPHC combined with intravenous chemotherapy for advanced ovarian cancer has better short-term efficacy and higher3-year survival rate,without increasing of the risk of adverse reactions,which is a safe and reliable treatment.